DeepMed Research

3D Medicines (Sichuan) Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2016-03-16

Employees: -

Market Cap: -

Website

Clinical Trials

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
Drug: placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

First Posted Date: 2023-11-09

Last Posted Date: 2025-05-20

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 390

Registration Number: NCT06123754

Locations: 🇨🇳
Tianjin cancer hospital, Tianjing, Tianjin, China

Phase I Trial of Envafolimab for Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Male

Interventions: Drug: Envafolimab with old manufacturing process
Drug: Envafolimab with new manufacturing process

First Posted Date: 2023-05-08

Last Posted Date: 2024-08-14

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 160

Registration Number: NCT05849311

Locations: 🇨🇳
Beijing Gaobo Boren Hosipital, Beijing, Beijing, China

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Phase 2

Recruiting

Conditions: Advanced Endometrial Cancer

Interventions: Drug: Envafolimab+Lenvatinib
Drug: Envafolimab

First Posted Date: 2021-11-09

Last Posted Date: 2024-11-29

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 108

Registration Number: NCT05112991

Locations: 🇨🇳
Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 16 locations

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors
Renal Cell Carcinoma
Non-small Cell Lung Cancer
Hepatocellular Carcinoma

Interventions: Drug: Lenvatinib + Envafolimab
Drug: Sunitinib

First Posted Date: 2021-08-27

Last Posted Date: 2024-08-23

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 170

Registration Number: NCT05024214

Locations: 🇨🇳
THE First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

and more 20 locations

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Phase 2

Not yet recruiting

Conditions: Biliary Tract Neoplasms

Interventions: Drug: Gemcitabine&Cisplatin
Drug: Envafolimab plus Gemcitabine&Cisplatin

First Posted Date: 2021-06-02

Last Posted Date: 2024-08-14

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 126

Registration Number: NCT04910386

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Phase 2

Recruiting

Conditions: Solid Tumor

Interventions: Drug: Envafolimab

First Posted Date: 2021-05-18

Last Posted Date: 2024-08-23

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 126

Registration Number: NCT04891198

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

KN035 for dMMR/MSI-H Advanced Solid Tumors

Phase 2

Recruiting

Conditions: Solid Tumor

Interventions: Biological: KN035

First Posted Date: 2018-09-12

Last Posted Date: 2024-08-23

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT03667170

Locations: 🇨🇳
Peking University Cancer Hospital, Peking University, Beijing, Beijing, China

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Phase 3

Active, not recruiting

Conditions: Biliary Tract Neoplasms

Interventions: Drug: KN035 plus Gemcitabine & oxaliplatin
Drug: Gemcitabine & oxaliplatin

First Posted Date: 2018-03-27

Last Posted Date: 2024-08-23

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 480

Registration Number: NCT03478488

Locations: 🇨🇳
The Chinese people's liberation army (PLA) 81hospital, Nanjing, Jiangsu, China

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: KN035

First Posted Date: 2017-08-14

Last Posted Date: 2022-02-08

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 35

Registration Number: NCT03248843

Locations: 🇯🇵
St. Marianna University School of Medicine Hospital, Kawasaki, Japan
🇯🇵
National Cancer Center Hospital, Tokyo, Japan

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: KN035

First Posted Date: 2017-04-05

Last Posted Date: 2022-03-03

Lead Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Target Recruit Count: 287

Registration Number: NCT03101488

Locations: 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy